Pediatric SLE

Introduction And Epidemiology

• Multisystem autoimmune connective tissue disorder.
• Characterized by loss of self-tolerance and production of antinuclear antibodies (ANA).
• Pediatric-onset systemic lupus erythematosus (pSLE) defined as disease onset before 16 or 18 years of age.
• Accounts for up to 20% of all lupus cases globally.
• Disease course in childhood more severe compared to adult-onset.
• Exhibits widespread organ involvement with poorer overall prognosis.
• Rare before 5 years of age; median age at diagnosis spans 11 to 12 years.
• Female predominance varies with age. Female-to-male ratio approaches 4:1 before puberty.
• Ratio increases to 8:1 or 9:1 during adolescent reproductive years.
• Increased risk documented among Hispanic, Asian, and Black populations.

Etiology

Pathogenesis Mechanism

Defective Apoptotic Clearance

• UV radiation damages cellular DNA, triggering programmed cell death.
• Defective clearance of apoptotic cell debris exposes intracellular nuclear antigens to immune system.

Role Of NETosis

• Neutrophil extracellular traps (NETs) serve as critical autoantigen reservoirs.
• Aberrant NETosis and impaired clearance increase exposure to dsDNA and histones.

Immune Dysregulation

• Plasmacytoid dendritic cells internalize NET-DNA via Toll-like receptor 9.
• Robust interferon secretion drives classic Type I interferon signature.
• T-cell stimulation promotes continuous autoreactive B-cell activation.
• Massive autoantibody (anti-dsDNA, ANA) production ensues.

Tissue Damage

• Circulating autoantibodies form immune complexes with nuclear antigens, defining a Type III hypersensitivity reaction.
• Immune complexes deposit in target tissues including glomeruli, dermis, and blood vessels.
• Local complement activation initiates proinflammatory cascade.
• Release of lysosomal enzymes and toxic free radicals causes irreversible target organ damage.
• Autoantibodies targeting specific blood cells (erythrocytes, platelets) trigger secondary Type II hypersensitivity destruction.

Clinical Manifestations

Constitutional Symptoms

Unexplained fever, extreme fatigue, severe malaise, anorexia, and weight loss are among the most common initial presentations in children and adolescents. Generalized lymphadenopathy and hepatosplenomegaly are also frequently observed.

Mucocutaneous Involvement

Skin and mucosal manifestations are present in the majority of patients.

• Malar Rash: A photosensitive, erythematous rash over the cheeks and nasal bridge that characteristically spares the nasolabial folds.
• Discoid Lupus: Hyperkeratotic, scarring lesions that are rare in childhood-onset SLE.
• Ulcers: Painless ulcerations commonly affecting the oral, buccal, palatal, or nasal mucosa.
• Alopecia: Non-scarring hair loss that is prominently frontal.
• Vascular and Other Skin Lesions: Patients may exhibit palmar erythema, petechiae, palpable purpura, livedo reticularis, chilblains, subacute cutaneous lupus, panniculitis, or digital gangrene.

Musculoskeletal Disease

Musculoskeletal complaints are frequent at presentation, often occurring within the first year of diagnosis.

• Arthritis: Typically a symmetrical polyarthritis affecting both large and small joints. The arthritis is generally painful but non-erosive and non-deforming.
• Other Manifestations: Tenosynovitis, myositis, myalgias, and arthralgias. Avascular necrosis and osteoporosis are important complications that frequently arise secondary to prolonged corticosteroid therapy.

Renal Involvement (Lupus Nephritis)

Lupus nephritis occurs in 50-80% of pediatric patients and is a leading cause of morbidity and mortality.

• Early/Silent Onset: Renal disease is often clinically asymptomatic initially, making routine blood pressure and urinalysis monitoring mandatory.
• Clinical Features: When symptomatic, it manifests with microscopic hematuria, proteinuria, and the presence of cellular (e.g., red blood cell) casts.
• Advanced Disease: Progression can lead to hypertension, generalized edema, nephrotic syndrome, and acute or chronic renal failure.

Neuropsychiatric Disease

SLE can affect both the central and peripheral nervous systems, and neuropsychiatric complications can occur independently of other apparent systemic disease activity.

• Central Nervous System: Manifestations include seizures, psychosis, acute confusional state, delirium, and chorea (which is notably more common in children than adults). Adolescents frequently present with mood disorders and cognitive dysfunction. Patients may also suffer from a severe, unremitting "lupus headache," which can be secondary to cerebral venous sinus thrombosis.
• Peripheral Nervous System: Features can include cranial nerve palsies, mononeuritis multiplex, or transverse myelitis.

Cardiovascular and Pulmonary Systems

• Cardiac: Inflammation can affect any layer of the heart, resulting in pericarditis, myocarditis, verrucous (Libman-Sacks) endocarditis, and conduction abnormalities. Premature atherosclerosis is a significant long-term complication that can lead to early myocardial infarction.
• Pulmonary: Features include pleuritis, pleural effusions, interstitial lung disease, pulmonary hypertension, pulmonary hemorrhage, and shrinking lung syndrome.

Hematologic Abnormalities

Immune-mediated cytopenias are frequent manifestations.

• Blood Cell Deficits: Patients commonly display Coombs-positive autoimmune hemolytic anemia, leukopenia, severe lymphopenia, and thrombocytopenia (which can manifest as severe menorrhagia in adolescent females). Anemia of chronic inflammation is also typical.
• Other Hematologic Conditions: Hypercoagulability associated with antiphospholipid antibodies creates a high risk for venous or arterial thrombosis. Patients with SLE are also uniquely susceptible to macrophage activation syndrome, a life-threatening complication characterized by a severe cytokine storm.

Gastrointestinal and Ocular Findings

• Gastrointestinal: Symptoms range from non-specific anorexia and chronic abdominal pain to pancreatitis, protein-losing enteropathy, peritonitis, mesenteric vasculitis, and bowel infarction.
• Ocular: Eye involvement includes keratoconjunctivitis sicca (dry eyes), episcleritis, scleritis, retinal vasculitis, optic neuritis, and papilledema..

Diagnostic Evaluation And Biomarkers

General Laboratory Investigations

• Complete Blood Count (CBC): Crucial for detecting cytopenias (leukopenia, lymphopenia, thrombocytopenia, hemolytic anemia).
• Acute Phase Reactants: Erythrocyte sedimentation rate (ESR) typically elevated during active disease.
• C-reactive protein (CRP) typically normal despite high ESR. Elevated CRP specifically indicates superimposed infection, active arthritis, or serositis.
• Renal Evaluation: Urinalysis mandatory for detecting proteinuria and microscopic hematuria. Assessment of cellular casts, serum urea, and creatinine.

Immunological Profile

Classification Criteria Sets

• Diagnosis remains clinical, supported by classification criteria developed originally for research homogeneity.

Management

• Requires lifelong multidisciplinary approach encompassing rheumatologist, nephrologist, and dermatologist.
• Therapy strictly tailored to specific organ involvement and acute disease severity.

General And Preventive Measures

• Photoprotection:
  • Strict avoidance of direct sun exposure.
  • Liberal application of broad-spectrum sunscreen (SPF >30) 3-4 times daily, 30 minutes prior to exposure.
• Nutritional Support:
  • Calcium and Vitamin D supplementation to actively prevent glucocorticoid-induced osteoporosis.
• Cardiovascular Health:
  • Monitor lipids, blood pressure, and BMI due to accelerated atherosclerosis risk.
  • Statins indicated for primary prevention in select high-risk pubertal patients.
• Vaccinations:
  • Inactivated vaccines (influenza, pneumococcal, hepatitis A) strongly recommended prior to immunosuppression.
  • Live vaccines strictly contraindicated during immunosuppressive therapy.

Pharmacotherapy Principles

• Antimalarials (Hydroxychloroquine):
  • Mainstay foundational therapy for all patients.
  • Prevents disease flares, treats cutaneous/MSK symptoms, improves lipid profile, reduces thrombotic risk.
  • Dose limited to <5 mg/kg/day to minimize retinal toxicity.
  • Adverse Events: Retinal Toxicity and Hyperpigmentation
  • Requires annual ophthalmologic examination with spectral-domain OCT.
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):
  • Naproxen or Ibuprofen provide symptomatic relief for mild arthritis, fever, and mild serositis.
  • Mandatory monitoring of renal function due to interstitial nephritis risk.
• Glucocorticoids:
  • Primary induction agent for moderate to severe disease.
  • Oral prednisolone 1-2 mg/kg/day utilized for persistent arthritis, cytopenias, or serositis.
  • Pulse intravenous methylprednisolone (30 mg/kg/day for 3-5 consecutive days) reserved for life-threatening disease including Class III/IV nephritis, severe CNS lupus, or pulmonary hemorrhage.
  • Rapid taper to lowest effective dose (<5 mg/day) crucial to avoid severe adverse effects (growth suppression, Cushingoid features, avascular necrosis, cataracts).

Immunosuppressants (Steroid-Sparing Agents)

• Methotrexate:
  • First-line steroid-sparing agent for persistent arthritis and cutaneous disease.
  • Requires folic acid supplementation and liver function monitoring.
• Azathioprine:
  • Predominantly utilized for maintenance therapy.
• Mycophenolate Mofetil (MMF):
  • Highly effective foundational drug for lupus nephritis induction and maintenance, and refractory cytopenias.
• Cyclophosphamide:
  • Potent alkylating agent restricted to severe organ-threatening disease (Class III/IV nephritis, pulmonary hemorrhage, severe CNS lupus).
  • Administered via structured IV protocols.
  • Carries high toxicity risk including severe myelosuppression, hemorrhagic cystitis, gonadal failure, and secondary malignancy.

Biologic Therapy

• Rituximab:
  • Chimeric monoclonal anti-CD20 antibody.
  • Depletes B-cells.
  • Specifically indicated for treatment-resistant glomerulonephritis and severe refractory hematological disease.
• Belimumab:
  • Fully human monoclonal antibody against B-lymphocyte stimulator (BLyS). Inhibits B-cell survival.
  • FDA approved for children >5 years.
  • Improves renal and nonrenal disease activity.
• Intravenous Immunoglobulin (IVIG):
  • Rescues acute life-threatening bleeding in severe thrombocytopenia or refractory immune cytopenias.

Management Of Lupus Nephritis

• Induction Phase (Proliferative Class III/IV): 6 months duration. Standardized regimen utilizes either IV Cyclophosphamide or high-dose oral Mycophenolate Mofetil, coupled with protocolized high-dose glucocorticoid taper.
• Maintenance Phase: Minimum 30 months therapy duration. Mycophenolate Mofetil preferred agent. Azathioprine acts as primary alternative.
• Refractory Disease: Warrants step-up to Calcineurin inhibitors (Tacrolimus) or Biologics (Rituximab).
• Treatment Goals: Achieve 25% reduction in proteinuria at 3 months, 50% reduction at 6 months.

Management Of Lupus Emergencies

Macrophage Activation Syndrome (MAS)

• Potentially fatal complication secondary to excessive systemic macrophage and T-cell proliferation causing massive cytokine storm.
• Clinical Presentation:
  • Unremitting continuous fever,
  • profound hepatosplenomegaly,
  • sudden icterus,
  • bleeding diathesis,
  • rapidly progressive encephalopathy.
• Laboratory Profile:
  • Paradoxical drop in ESR caused by hypofibrinogenemia.
  • Marked hyperferritinemia (>684 ng/mL),
  • pancytopenia,
  • hypertriglyceridemia,
  • elevated transaminases.
• Treatment:
  • Immediate initiation of pulse IV methylprednisolone.
  • Cyclosporine A added promptly for steroid-refractory disease.

Antiphospholipid Syndrome (APS)

• Secondary APS highly prevalent, affecting 9-14% of pSLE patients. Carries risk of catastrophic rapid deterioration.
• Clinical Features:
  • Venous thrombosis (deep vein thrombosis, cerebral sinus thrombosis),
  • arterial thrombosis (ischemic stroke),
  • livedo reticularis,
  • recurrent fetal loss in adolescents.
• Laboratory Profile:
  • Positive Lupus anticoagulant,
  • elevated Anticardiolipin IgG/IgM,
  • positive Anti-Beta-2 glycoprotein 1.
• Treatment Protocol:
  • Asymptomatic antibody carriers receive prophylactic low-dose aspirin.
  • Confirmed thrombotic events mandate lifelong anticoagulation with Warfarin or Low Molecular Weight Heparin.

Neonatal Lupus Erythematosus (NLE)

• Result of passively acquired maternal IgG autoantibodies, specifically Anti-Ro (SSA) and Anti-La (SSB) transplacentally crossing to fetus.
• Cutaneous Features:
  • Erythematous, annular, macular plaques over face and periorbital regions (owl-eye appearance).
  • Rash resolves spontaneously over 3-6 months as maternal antibodies clear, leaving no scarring.
• Systemic Features:
  • Transient hepatobiliary disease,
  • thrombocytopenia,
  • neutropenia,
  • anemia.
• Cardiac Complications:
  • Congenital Heart Block (CHB).
  • Third-degree complete heart block causes permanent destruction of conducting system, manifesting as fetal bradycardia, hydrops fetalis, or postnatal heart failure.
• Management Protocol:
  • Weekly fetal echocardiography from 16 to 22 weeks gestation for antibody-positive mothers.
  • Maternal administration of Dexamethasone prevents inflammatory fetal cardiac injury.
  • Maternal Hydroxychloroquine significantly reduces CHB recurrence risk. Third-degree CHB mandates permanent postnatal cardiac pacing.

Prognosis And Monitoring

• Advancements in protocolized pharmacotherapy have greatly improved survival metrics. Five-year and 10-year survival rates approach 99% and 97% respectively.
• Early Mortality Drivers: Intercurrent severe infections, macrophage activation syndrome, severe lupus cerebritis, and uncontrolled rapidly progressive lupus nephritis.
• Late Morbidity Drivers: Accelerated atherosclerosis causing early myocardial infarction. Chronic corticosteroid use risking osteoporosis, avascular necrosis, severe growth failure, cataracts, and diabetes. Progressive renal damage culminating in end-stage renal disease (ESRD) necessitating dialysis or transplantation.
• Monitoring Strategy: Routine clinical assessment utilizing Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. Score ranges from 0 to 105; clinical target requires maintaining score <4.
• Continuous multidisciplinary pediatric care and structured subsequent transition to adult rheumatology are absolutely imperative for lifelong disease control.